Lexicon Pharmaceuticals 미래 성장

Future 기준 확인 2/6

Lexicon Pharmaceuticals (는) 각각 연간 29.3% 및 50.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 35.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -94.2% 로 예상됩니다.

주요 정보

29.3%

수익 성장률

35.7%

EPS 성장률

Biotechs 수익 성장	26.8%
매출 성장률	50.6%
향후 자기자본 수익률	-94.2%
애널리스트 커버리지	Good
마지막 업데이트	21 Dec 2024

최근 미래 성장 업데이트

Recent updates

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Oct 16

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

수익 및 매출 성장 예측

NasdaqGS:LXRX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	75	-135	N/A	N/A	4
12/31/2026	27	-154	N/A	N/A	6
12/31/2025	13	-158	N/A	N/A	6
12/31/2024	11	-211	N/A	N/A	6
9/30/2024	5	-216	-208	-208	N/A
6/30/2024	4	-202	-196	-196	N/A
3/31/2024	2	-194	-186	-185	N/A
12/31/2023	1	-177	-162	-162	N/A
9/30/2023	1	-158	-135	-133	N/A
6/30/2023	0	-131	-112	-111	N/A
3/31/2023	0	-110	-99	-97	N/A
12/31/2022	0	-102	-90	-89	N/A
9/30/2022	0	-97	-90	-90	N/A
6/30/2022	0	-97	-88	-88	N/A
3/31/2022	0	-90	-87	-85	N/A
12/31/2021	0	-88	-88	-87	N/A
9/30/2021	0	-68	-100	-98	N/A
6/30/2021	7	38	38	-122	N/A
3/31/2021	16	-13	14	-146	N/A
12/31/2020	24	-59	17	-143	N/A
9/30/2020	33	-104	27	-133	N/A
6/30/2020	320	39	98	98	N/A
3/31/2020	321	85	117	117	N/A
12/31/2019	322	130	114	114	N/A
9/30/2019	330	164	111	111	N/A
6/30/2019	43	-89	-102	-102	N/A
3/31/2019	47	-101	-128	-127	N/A
12/31/2018	63	-121	-149	-149	N/A
9/30/2018	81	-126	-155	-155	N/A
6/30/2018	101	-129	N/A	-167	N/A
3/31/2018	99	-130	N/A	-147	N/A
12/31/2017	92	-123	N/A	-185	N/A
9/30/2017	80	-133	N/A	-200	N/A
6/30/2017	81	-138	N/A	-202	N/A
3/31/2017	89	-141	N/A	-217	N/A
12/31/2016	79	-131	N/A	-176	N/A
9/30/2016	188	-22	N/A	139	N/A
6/30/2016	160	-22	N/A	149	N/A
3/31/2016	141	-11	N/A	165	N/A
12/31/2015	130	-5	N/A	185	N/A
9/30/2015	24	-94	N/A	-86	N/A
6/30/2015	24	-100	N/A	-81	N/A
3/31/2015	24	-98	N/A	-69	N/A
12/31/2014	23	-100	N/A	-76	N/A
9/30/2014	3	-115	N/A	-93	N/A
6/30/2014	3	-106	N/A	-96	N/A
3/31/2014	2	-109	N/A	-97	N/A

애널리스트 미래 성장 예측

수입 대 저축률: LXRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: LXRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: LXRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: LXRX 의 수익(연간 50.6% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: LXRX 의 수익(연간 50.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: LXRX (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/05 18:57
장 마감 주가	2025/01/03 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Lexicon Pharmaceuticals, Inc. 15 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Yigal Nochomovitz	Citigroup Inc
Kevin Kedra	G. Research, LLC
Joseph Pantginis	H.C. Wainwright & Co.

Lexicon Pharmaceuticals 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 13% to US$4.68

Consensus revenue estimates decrease by 24%

Price target increased by 16% to US$6.25

Price target decreased by 16% to US$5.40

Consensus revenue estimates increase by 33%

Consensus revenue estimates decrease by 41%

Recent updates

Lexicon Pharmaceuticals, Inc. Announces CFO Changes

Lexicon Appoints Scott Coiante as Chief Financial Officer

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Price target decreased by 13% to US$4.68

Lexicon Pharmaceuticals, Inc. Announces Board Changes

Consensus revenue estimates decrease by 24%

New major risk - Financial position

Price target increased by 16% to US$6.25

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. Publishes Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Price target decreased by 16% to US$5.40

Lexicon Pharmaceuticals, Inc. Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

Consensus revenue estimates increase by 33%

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial

Consensus revenue estimates decrease by 41%

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces CEO Changes

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

New major risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors